Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to analysts.
Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.
A negative reaction for BT Group PLC (LSE:BT.A) shares was understandable said Barclays after the UK telecoms regulator proposed a ban on inflation-linked mid-contract price rises, which led to large bill hikes earlier this year.
Ofcom yesterday proposed rules to remove the inflation linkage in consumer contracts, which is a departure from the prior strategy of leaving the retail market alone, analysts at the bank pointed out.
JD Sports Fashion PLC (LSE:JD.) is one of two standouts in a generally strong sportswear sector, according to the analysts at JP Morgan.
The trainer specialist offers the best combination of growth, margins, returns and valuation in the sector, with well-underpinned estimates for next year and a strong Christmas trading update ahead as suggested by recent peer reporting and US credit card data for the sector.
WPP PLC (LSE:WPP) fell 1.1% after JPMorgan downgraded to ‘neutral’ from ‘overweight’ to reflect the slowing US macroeconomic environment.
The broker made the move in a sector review in which it said the outlook for 2024 is very similar to that 12 months ago.
Liberum has reiterated its 'buy' rating on Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) stock after the group unveiled a maiden JORC 2012-compliant feldspar resource estimate at its Ewoyaa spodumene lithium project in Ghana.
The estimate stands at 15.7 million tonnes at a concentration of 40.2% feldspar.
AJ Bell and Hargreaves Lansdown stand to lose a chunk of their profits following the warning from the Financial Conduct Authority (FCA) over the interest paid on 'idle cash' held in customers' investment accounts, according to US bank Citi.
In a 'dear CEO' letter to the investment platforms, the FCA spelt out its expectations for firms' platform cash revenues under Consumer Duty legislation, Citi noted.
hVIVO PLC’s respiratory syncytial virus (RSV) drug contract announced on Wednesday “should be taken well by the market”, reckon Cavendish analysts, despite shares already ripping 80% higher year to date
This full-service, end-to-end contract is forecast to bring in revenues of £16.8 million from 2023 to 2025, with the bulk expected in 2024.